Nicholas Vogelzang, MD
Enriched profileMedical Oncologist and Chairman of Medical Oncology, Comprehensive Cancer Centers of Nevada; Site Research Leader, US Oncology Research (position held until his death on September 20, 2022, deceased, not an active current role) · Comprehensive Cancer Centers of Nevada
Nicholas Vogelzang is Medical Oncologist and Chairman of Medical Oncology, Comprehensive Cancer Centers of Nevada; Site Research Leader, US Oncology Research (position held until his death on September 20, 2022, deceased, not an active current role) at Comprehensive Cancer Centers of Nevada. OpenAlex indexes 1,129 publications with 69,644 citations (h-index 115); ClinicalTrials.gov lists 2 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 5% of Hematology / Oncology profiles in the findmyKOL directory. Clarivate lists Nicholas Vogelzang as a Highly Cited Researcher (Clinical Medicine, 2020-2024).
Data verified 14 Aug 2026
Overview
Updated 27 Aug 2026
Nicholas J. Vogelzang is Medical Oncologist and Chairman of Medical Oncology, Comprehensive Cancer Centers of Nevada. The public record shows 1,129 publications with 69,644 citations (h-index 115), centered on Prostate Cancer Treatment and Research, Renal cell carcinoma treatment, Bladder and Urothelial Cancer Treatments. It also documents an investigator role on 2 registered clinical trials.
- Most recent indexed publication: 2023 · Journal of clinical oncology
- Top research focus: Prostate Cancer Treatment and Research
- 2 registered trials on ClinicalTrials.gov
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 8 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 511.
Clinical & industry
trials, payments and federal fundingFederally funded research awards.
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 2 registered studies on ClinicalTrials.gov. The most recent:
Industry payments
21 companies reported payments to CMS in program years 2021–2022. These are public disclosures, not judgments. The latest:
- Bayer HealthCare Pharmaceuticals Inc.Program year20222 payments
- GENZYME CORPORATIONProgram year20222 payments
- Celgene CorporationProgram year20222 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2022)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Genitourinary & hormones
34.3%Androgen33.9%Testosterone cypionate100%Part B, office-administered≥19 patients5-alpha Reductase Inhibitor0.2%Finasteride100%Part D≥23 patientsMetabolism & gastrointestinal
29%Other antiemetics26.8%Fosaprepitant100%Part B, office-administered≥24 patientsSerotonin-3 Receptor Antagonist1.9%Palonosetron hcl100%Part B, office-administered≥26 patientsBlood & clotting
24.7%Erythropoiesis-stimulating Agent24.6%Darbepoetin alfa100%Part B, office-administered≥14 patientsFactor Xa inhibitor0.1%Eliquis100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Publications
Updated 27 Aug 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- EphrinB2 Inhibition and Pembrolizumab in Metastatic Urothelial Carcinoma.
Journal of clinical oncology
Clinical Trial2023 - Orteronel for Metastatic Hormone-Sensitive Prostate Cancer: A Multicenter, Randomized, Open-Label Phase III Trial (SWOG-1216).
Journal of clinical oncology
Clinical Trial2022 - Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials.
Clinical cancer research
Clinical Trial2022 - Serial ctDNA analysis predicts clinical progression in patients with advanced urothelial carcinoma.
British journal of cancer
Article2022 - Using Geriatric Assessment to Guide Conversations Regarding Comorbidities Among Older Patients With Advanced Cancer.
JCO oncology practice
Clinical Trial2022
Most-cited works
by citation count (OpenAlex)- 01Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma3,395 citations2017
- 02Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer3,348 citations2013
- 03
- 04Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer2,840 citations2015
- 05
Network
Updated 27 Aug 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 27 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Mentions by others
where others cite or feature them- Other
onclive.com/authors/nicholas-j-vogelzang-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 27 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →healthgrades.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →healthgrades.com ↗
- Internship
residency, and chief residency in Internal Medicine, Rush-Presbyterian-St. Luke's Medical Center, Chicago
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →en.wikipedia.org ↗ - Board Certified
American Board of Internal Medicine, Internal Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →healthgrades.com ↗ - Board Certified
American Board of Internal Medicine, Medical Oncology
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →healthgrades.com ↗
Editorial & leadership roles
journal and society appointments- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cccnevada.com ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →en.wikipedia.org ↗
- Head of Genitourinary Oncology and Clinical Professor of Medicine
University of Nevada School of Medicine (Las Vegas and Reno), from 2004
2004verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cccnevada.com ↗
Highly Cited Researcher
Clarivate's annual list, by award category and year- Clinical Medicine20202021202220232024verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →clarivate.com ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →giantsofcancercare.com ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →en.wikipedia.org ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →en.wikipedia.org ↗
Secondary affiliations
appointments beyond the home institution- US Oncology Network / US Oncology Research
Medical Director, Research Executive Committee; Associate Chair, Developmental Therapeutics and GU Committees
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cccnevada.com ↗ - University of Nevada School of Medicine
Clinical Professor of Medicine (concurrent with CCCN practice)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cccnevada.com ↗
Media & interviews
press, podcasts and appearances- OncLive author/video archive
multiple recorded interviews on GU oncology topics (e.g., ASCO abstract reviews, axitinib in RCC, abiraterone/enzalutamide sequencing, radium-223/ALSYMPCA trial, PROSPECT trial)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗ - Regular contributing author
CURE Today (patient-facing oncology publication)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →curetoday.com ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Fadi Braiteh, MD
Comprehensive Cancer Centers of Nevada
Oscar Goodman, MD
Comprehensive Cancer Centers of Nevada
Raul Meoz, MD
Comprehensive Cancer Centers of Nevada
Edwin Kingsley, MD
Comprehensive Cancer Centers of Nevada